Diagnosis and Management of Albuminuria

Diagnostic Approach

• The American Diabetes Association recommends using albumin-to-creatinine ratio (ACR) in a random spot collection as the preferred method for diagnosis, with first-void or morning collections preferred due to diurnal variation 1, 2, 3
• Factors that can temporarily elevate urinary albumin, such as exercise within 24 hours, infection, fever, congestive heart failure, marked hyperglycemia, and marked hypertension, should be ruled out before diagnosis 3
• A single measurement of microalbuminuria is not sufficient for diagnosis; two of three specimens collected within a 3- to 6-month period should be abnormal before confirming a diagnosis of microalbuminuria, as recommended by the American Diabetes Association 1, 2
• Specific assays are required to detect microalbuminuria, as standard hospital laboratory assays for urinary protein are not sufficiently sensitive, as noted by the American Journal of Kidney Diseases 1, 2
• Reagent strips/dipsticks for microalbumin screening show acceptable sensitivity (95%) and specificity (93%) when used by trained personnel, but all positive tests should be confirmed by more specific methods, according to the American Diabetes Association 1
• The following categories are defined by the American Diabetes Association and the American Journal of Kidney Diseases:

4, 5, 1, 3, 6, 7

Treatment Approach

• The American Journal of Kidney Diseases recommends starting with an ACE inhibitor or ARB, even in normotensive patients with albuminuria >30 mg/g who are at high risk of kidney disease progression, with a strength of evidence rated as high 8, 9
• The American College of Physicians recommends starting patients on an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) as first-line therapy to reduce albuminuria and slow progression of kidney disease, even with normal eGFR, with a strength of evidence rated as high 8
• Medication adjustment should include replacing or adding an ACE inhibitor or ARB to the current regimen and titrating to maximum tolerated dose, as done in clinical trials, with a strength of evidence rated as moderate 8, 10
• The American Journal of Kidney Diseases recommends monitoring serum potassium and creatinine after initiation of ACE inhibitor or ARB therapy, with a frequency of monitoring dependent on individual patient risk factors 10
• SGLT2 inhibitors or GLP-1 receptor agonists may be considered in type 2 diabetes to reduce CKD progression risk, as recommended by the American Heart Association and the American Diabetes Association, with a strength of evidence rated as moderate 11, 12, 3, 13, 14, 15, 16, 4, 17, 18, 19
• Lifestyle modifications, including sodium restriction (<2g/day), weight optimization (BMI 20-25 kg/m²), and regular exercise (30 minutes, 5 times weekly), are recommended by the American Diabetes Association, with a strength of evidence rated as high 11, 20, 21, 17, 3, 16, 15, 22, 13
• The American Diabetes Association recommends a target blood pressure of <130/80 mmHg, with regular monitoring of blood pressure necessary to ensure target achievement, as recommended by the American Heart Association 23, 24, 3, 12, 13, 15, 16, 14

Monitoring and Referral

• Annual screening for microalbuminuria is recommended for patients with diabetes, with a definition of microalbuminuria as an ACR of 30-299 mg/g creatinine, as recommended by the American Diabetes Association and the American College of Physicians 24, 8, 4
• Measurement of serum creatinine at least annually is recommended to estimate GFR and stage the level of chronic kidney disease, if present, according to the American Diabetes Association 24
• Monitor response to treatment by following albumin-to-creatinine ratio (ACR) every 3-6 months and renal function (eGFR) at least annually, as recommended by the American Journal of Kidney Diseases, the National Kidney Foundation, and the American Diabetes Association, with a strength of evidence rated as high 4, 17, 3, 16, 15, 22, 13
• A doubling of albumin-to-creatinine ratio or a change in estimated GFR >20% requires further evaluation, according to the American Journal of Kidney Diseases, with a strength of evidence rated as moderate 25
• Referral to nephrology should be considered if ACR increases to ≥300 mg/g despite treatment, if eGFR declines to <45 mL/min/1.73 m², or if blood pressure becomes refractory to treatment with multiple agents, as recommended by the American Journal of Kidney Diseases and the Anaesthesia journal 6, 11, 25, 26, 27, 14
• Nephrology referral should also be considered if difficulties occur in the management of hypertension or hyperkalemia 3